CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
PRODUCTS & THERAPIES
218 条相关资料
Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant
Cilta-cel 在体弱 RRMM 中仍然有效，但衰弱与生存期缩短和毒性增加相关，支持制定个体化的 CAR-T 策略。
Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.
Anito-cel 治疗在重度经治的复发/难治性多发性骨髓瘤患者中导致了高缓解率。3 级或更高级别的细胞因子释放综合征和 ICANS 罕见。（由 Arcellx 和 Kite，一家吉利德公司资助；ClinicalTrials.gov 注册号：NCT04155749。）
Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy.
Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma.
Cost-Effectiveness of Cilta-cel in Lenalidomide-Refractory Multiple Myeloma: An Analysis of the CARTITUDE-4 Trial.
相对于标准治疗，cilta-cel 预计在治疗来那度胺难治性多发性骨髓瘤中展现出经济上的绝对成本效益优势。
The future of ciltacabtagene autoleucel in multiple myeloma has just begun.
Ciltacabtagene autoleucel heralds the arrival of fixed-duration therapies in myeloma.
Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.
Adaptive Bridging and Holding Therapy Frequently Reduces Tumor Burden and Is Associated With Reduced Toxicity After CAR-T Cell Therapy in Multiple Mye
输注前更深的缓解与 BCMA 靶向 CAR-T 治疗后显著更低的毒性相关，表明输注前的疾病控制是毒性潜在可干预的决定因素。强化等待与桥接策略在高强度预处理患者中可降低疾病负荷，且安全可行，支持通过前瞻性验证以缓解适应性桥接来改善 RRMM 中 CAR-T 治疗的安全性。
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
这是一项 II 期注册临床试验，评估细胞治疗用于多发性骨髓瘤的疗效与安全性。当前状态：招募中。计划入组 44 例。试验地点：美国 · 罗切斯特（共 1 个中心）。登记号：NCT06940297。
Real-world treatment patterns and outcomes of patients treated with commercial chimeric antigen receptor T-cell therapy for relapsed/refractory multip
这项真实世界研究为商业化 CAR-T 疗法的决策增添了新的证据，并支持制定临床最佳实践和指南、支付方决策以及 RRMM 中 CAR-T 治疗的卫生系统规划。
Overcoming Trial Exclusion: A Multicenter Analysis of Hemodialysis Multiple Myeloma Patients Who Underwent BCMA-Directed CAR-T Therapy.
Non-ICANS neurologic toxicity after BCMA CAR-T therapy: a systematic review and meta-analysis of 4630 patients with multiple myeloma.
Prophylactic dexamethasone at the time of absolute lymphocyte expansion does not mitigate risk or event-free survival for immune effector cell associa
Robust CD4(+) CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma.
MEMBER ACCOUNT
登录成功会直接打开下一页。
